Search

Your search keyword '"Kristian Cibulskis"' showing total 144 results

Search Constraints

Start Over You searched for: Author "Kristian Cibulskis" Remove constraint Author: "Kristian Cibulskis"
144 results on '"Kristian Cibulskis"'

Search Results

1. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition

2. Systematic genomic and translational efficiency studies of uveal melanoma.

3. Genetic mapping and exome sequencing identify variants associated with five novel diseases.

4. Supplementary Table 2 from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

5. Supplementary Table S4 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma

6. Supplementary Table S3 from Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets

7. Supplementary Methods, Figures S1 - S20 from Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets

8. Supplementary Methods, Figure Legends, Figures S1 - S6, Tables S1, S3 - S6, S8 - S15, S17 from The Genomic Landscape of Pediatric Ewing Sarcoma

9. Supplementary Table 6 from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

10. Supplementary Table 4 from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

11. Supplementary Table 3 from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

12. Supplementary Figure 1 from Temporal Dissection of Tumorigenesis in Primary Cancers

13. Supplementary File 1 from Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets

14. Supplementary Table 1 from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

15. Supplementary Table S7 from The Genomic Landscape of Pediatric Ewing Sarcoma

16. Supplementary Figure 2 from Temporal Dissection of Tumorigenesis in Primary Cancers

17. Supplementary Figure Legends 1-4, Methods from Temporal Dissection of Tumorigenesis in Primary Cancers

18. Supplementary Table 5 from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

19. Supplementary Table 2 from Temporal Dissection of Tumorigenesis in Primary Cancers

20. Supplementary Table Legends from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma

21. Supplementary Figures from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

22. Supplementary Figure 3 from Temporal Dissection of Tumorigenesis in Primary Cancers

23. Supplementary File 3 from Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets

24. Supplementary Figure 4 from Temporal Dissection of Tumorigenesis in Primary Cancers

25. Supplementary Table 1 from Temporal Dissection of Tumorigenesis in Primary Cancers

26. Data from The Genomic Landscape of Pediatric Ewing Sarcoma

27. Supplementary File 2 from Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets

28. Data Supplement from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

29. A genome-wide mutational constraint map quantified from variation in 76,156 human genomes

30. Landscape of multi-nucleotide variants in 125,748 human exomes and 15,708 genomes

31. Erratum: Addendum: The mutational constraint spectrum quantified from variation in 141,456 humans

32. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

33. Calling Somatic SNVs and Indels with Mutect2

34. The mutational constraint spectrum quantified from variation in 141,456 humans

35. Abstract A1-15: Systematic genomic characterization of uveal melanoma

36. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes

37. Comprehensive genomic characterization of head and neck squamous cell carcinomas

38. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma

39. Systematic genomic and translational efficiency studies of uveal melanoma

40. Integrated genomic characterization of oesophageal carcinoma

41. Exome sequencing of pleuropulmonary blastoma reveals frequent biallelic loss of TP53 and two hits in DICER1 resulting in retention of 5p-derived miRNA hairpin loop sequences

42. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine

43. Whole exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer

44. Genetic and Clonal Dissection of Murine Small Cell Lung Carcinoma Progression by Genome Sequencing

45. Integrative and Comparative Genomic Analysis of Lung Squamous Cell Carcinomas in East Asian Patients

46. Abstract 5108: Somatic small variant and copy number alteration calling with the Genome Analysis Toolkit

47. Landscape of genomic alterations in cervical carcinomas

48. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors

49. The Somatic Genomic Landscape of Glioblastoma

50. Mutational heterogeneity in cancer and the search for new cancer genes

Catalog

Books, media, physical & digital resources